Decapeptyl 6 month formulation

• Research type

  Research Study

• Full title

  Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score changes during initiation of Androgen Deprivation Therapy (ADT) with triptorelin (22.5mg) in patients with advanced prostate cancer (PCa): A phase III, single arm multicentre study

• IRAS ID

  31929

• Sponsor organisation

  Ipsen Ltd

• Eudract number

  2009-012786-58

• ISRCTN Number

  requested

• Research summary

  N/A

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  09/H0803/138

• Date of REC Opinion

  7 Dec 2009

• REC opinion

  Further Information Favourable Opinion